Dr. Payne’s Team Saves Employee. Read more and watch the video

Phoenix Neurological Associates, LTD was just named one of seven international centers of Excellence for Guillan Barre and CIDP. Read more

BITE NITE 2010
Our first fundraiser took place on June 5, 2010 at Scottsdale Resort and Conference Center. PNA Center for Neurological Research teamed up with the ALS Association Arizona Chapter to co-host a night dedicated to ALS (Lou Gehrig’s Disease). BITE NITE consisted of 5 top Valley Restaurants, 5th and Wine, Cien Agaves Tacos & Tequila, Oregano's Pizza Bistro and Va Bene who served up samplers of their best dishes, with great entertainment by our favorite local band Dearspeak, with silent and live auctions. The night was an absolute blast and a success. People enjoyed great food while enjoying each other’s company for a night that was dedicated to funding ALS research. Thank you for everyone who truly made this night a success. Due to the positive praise and feedback, BITE NITE will be an annual event, so if you weren’t able to attend, we look forward to seeing you there next year! Thanks again for your support, dedication and contributions, we couldn’t have made this night possible without you.

Check out photos from BITE NITE here.

Tretinoin and Pioglitazone HCL Combination Therapy in Amyotrophic Lateral Sclerosis

Trial Status
Open for Enrollment

What is the Purpose of this Study?
The devastating nature of this disease suggests that a drug cocktail may offer the best chance of attaining a significant reduction in disease progression. Therefore a trial of Riluzole, in combination with Pioglitazone HCL, a FDA-approved PPAR gamma agent for type II diabetes, and Tretinoin, a FDA-approved retinoid for acute procrymyclonic leukemia is proposed.

Who is Eligible to Participate?
Patients diagnosed with Amyotrophic Lateral Sclerosis who are currently being treated with Riluzole, with no history of liver disease, heart disease or diabetes. Patients must also meet all other inclusion and exclusion criteria explained in further detail by the study coordinator

What is involved in this Study?
This is a double-blinded, placebo controlled study. 2/3 of patients will receive Tretinin and Pioglitazone Hcl in conjunction with their Riluzole, and 1/3 will receive placebo in conjunction with their Riluzole. Your first visit is to determine if you are eligible to participate in the study. This visit consists of a Forced Vital Capacity test to determine your lung functioning, blood tests; an EKG, a questionnaire as well as a lumbar puncture will be performed to determine your baseline levels. You will receive drug approximately 4 weeks later, and every 4 weeks you will return to clinic for drug dispensing, blood tests and neuro exams.

How long is the Study?
It is approximately 32 weeks long. You will be on study drug for 24 weeks.

For More Information Contact: Nicole C. Hank, MHSM, study coordinator, at 602-258-3354 ext 137 or nhank@pnal.net or call the Main line at 602-258-3354